Esperion Says It Enters Into A Royalty Purchase Deal With Omers Life Sciences, Under Which It Got $304.7M In Exchange For 100% Interest In Esperion's Royalty Entitlement On Daiichi Sankyo Europe's Net Sales Of Bempedoic Acid Products In Europe

6/28/24 7:06:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ESPR alert in real time by email

Get the next $ESPR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ESPR

Date	Price Target	Rating	Analyst
6/20/2024	$2.50	Neutral → Underperform	BofA Securities
1/3/2024		Buy → Neutral	BofA Securities
11/20/2023		Neutral	JP Morgan
8/1/2023		Under Perform → Market Perform	Northland Capital
6/15/2023	$1.25 → $4.00	Underperform → Buy	BofA Securities
3/16/2023	$1.00	Market Perform → Under Perform	Northland Capital
3/16/2023	$8.00 → $1.50	Neutral → Underperform	BofA Securities
3/7/2023	$6.50 → $7.00	Underperform → Neutral	Credit Suisse

More analyst ratings

$ESPR
Press Releases

Fastest customizable press release news feed in the world

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsAt Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and ca
11/21/24 8:00:00 AM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo – ANN ARBOR, Mich., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the presentation of an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. These data were presented today in an oral featured science presentation at the 2024 American Heart Association (AHA) Scientific Sessions, which took place from November 16-18, 2024, in Chicago, IL. Additionally, two exploratory analyses from the CLEAR Outcome
11/18/24 10:30:00 AM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest and become exercisable as to 25 percent of the sha
11/8/24 4:15:00 PM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care

$ESPR
Leadership Updates

Live Leadership Updates

Esperion Appoints Ben Halladay Chief Financial Officer
ANN ARBOR, Mich., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior position of Senior Director, Financial Planning and Analysis, effective as of today. He will serve as a member of the executive management team and report to Sheldon Koenig, President and Chief Executive Officer. "We are thrilled to have Ben take on this expanded role on the Esperion leadership team with his promotion to CFO," said Sheldon Koenig, President and CEO of Esperion. "Ben has made significant contributions since joining the company in 2020, supporting our finance organization during a tra
11/16/22 4:00:00 PM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion's Board of Directors. Mr. Carroll will serve as a Class I director with a term expiring at the 2023 annual meeting of stockholders. "On behalf of the Esperion team and our directors, I am excited to welcome Marty as Chairperson of the Esperion Board. With his significant experience, Marty will provide additional leadership and strategic guidance to our Board as we continue to commercialize our medicines and advance our pipeline," said Sheldon Koenig, president and chief executive officer of Esperion. "Marty's expertise will be critical
6/1/22 4:00:00 PM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
ANN ARBOR, Mich., April 28, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual meeting of stockholders. Mr. Rocamboli fills the newly created vacancy resulting from Dr. Mark McGovern's retirement from the Board. "On behalf of the Esperion team and our directors, I am very pleased to welcome Stephen to the Esperion Board. Stephen's extensive experience as a senior business and legal executive for multiple public life science organizations will be a great asset for Esperion as we continue to commercialize our medicines and grow our pipeline," said Sheldon Koenig, president and ch
4/28/22 4:00:00 PM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care

$ESPR
Financials

Live finance-specific insights

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four Weeks of Q3 2024 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the third quarter ended September 30, 2024, and provided a business update. "The year to date has been transformational for Es
11/7/24 6:00:00 AM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
Esperion to Report Third Quarter 2024 Financial Results on November 7
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for appro
10/24/24 8:00:00 AM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
– Total Revenue Increased 186% Year-over-Year to $73.8 Million withU.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from First Quarter, with ~11% Increase During Final Four Weeks of Second Quarter – – Completed Transformational Transaction by Monetizing European Royalties on Bempedoic Acid Product Sales to OMERS Life Sciences for $304.7 Million and Allocated Proceeds for Early, Discounted Payoff and Termination of Oberland Capital Revenue Interest Facility – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported finan
8/12/24 6:00:00 AM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care

Esperion Says It Enters Into A Royalty Purchase Deal With Omers Life Sciences, Under Which It Got $304.7M In Exchange For 100% Interest In Esperion's Royalty Entitlement On Daiichi Sankyo Europe's Net Sales Of Bempedoic Acid Products In Europe

Chat with this insight

Recent Analyst Ratings for $ESPR

$ESPR Press Releases

Fastest customizable press release news feed in the world

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

$ESPR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer Warren Eric sold $427 worth of shares (197 units at $2.17), decreasing direct ownership by 0.12% to 162,355 units (SEC Form 4)

Chief Commercial Officer Warren Eric sold $227 worth of shares (107 units at $2.12), decreasing direct ownership by 0.07% to 162,552 units (SEC Form 4)

President and CEO Koenig Sheldon L. sold $26,132 worth of shares (14,550 units at $1.80), decreasing direct ownership by 2% to 752,266 units (SEC Form 4)

$ESPR Leadership Updates

Live Leadership Updates

Esperion Appoints Ben Halladay Chief Financial Officer

Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors

Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors

$ESPR Financials

Live finance-specific insights

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion to Report Third Quarter 2024 Financial Results on November 7

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

$ESPR Market Insights

Live Market Insights

Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target

Esperion Therapeutics shares are trading lower after the company announced that it entered into a Royalty Purchase Agreement with OMERS Life Sciences. The stock initially traded higher, but it has since reversed.

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

$ESPR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

$ESPR FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

$ESPR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ESPR SEC Filings

Esperion Therapeutics downgraded by BofA Securities with a new price target

Esperion Therapeutics downgraded by BofA Securities

JP Morgan resumed coverage on Esperion Therapeutics

SEC Form 10-Q filed by Esperion Therapeutics Inc.

Esperion Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form S-8 filed by Esperion Therapeutics Inc.

Recent Analyst Ratings for
$ESPR

$ESPR
Press Releases

$ESPR
Insider Trading

$ESPR
Leadership Updates

$ESPR
Financials

$ESPR
Market Insights

$ESPR
Large Ownership Changes

$ESPR
FDA approvals

$ESPR
Analyst Ratings

$ESPR
SEC Filings